本妥昔单抗联合序贯使用丙卡巴肼、环磷酰胺和泼尼松龙治疗霍奇金淋巴瘤相关的伴有严重梗阻性肝衰竭的消失性胆管综合征（VBDS）。
Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.
作者信息
Fong Min, Boyle Stephen, Gutta Naadir
机构信息
Queensland Health, Brisbane, Queensland, Australia.
Haematology, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
出版信息
BMJ Case Rep. 2019 Feb 21;12(2):e227676. doi: 10.1136/bcr-2018-227676.
Abstract
We present a novel treatment protocol that was successful in the management of Hodgkin's-associated vanishing bile duct syndrome, a rare but serious complication of Hodgkin's lymphoma. We believe that publication of this treatment protocol and the rationale for its development will be of interest to anyone faced with treating this challenging condition.
摘要
我们提出了一种新的治疗方案，该方案成功地用于治疗霍奇金淋巴瘤相关的胆管消失综合征，这是霍奇金淋巴瘤一种罕见但严重的并发症。我们相信，公布这一治疗方案及其制定的基本原理，将对任何面临治疗这一具有挑战性病症的人有所帮助。
相似文献
1
Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.本妥昔单抗联合序贯使用丙卡巴肼、环磷酰胺和泼尼松龙治疗霍奇金淋巴瘤相关的伴有严重梗阻性肝衰竭的消失性胆管综合征（VBDS）。
BMJ Case Rep. 2019 Feb 21;12(2):e227676. doi: 10.1136/bcr-2018-227676.
2
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.将本妥昔单抗维迪辛纳入晚期经典型霍奇金淋巴瘤的一线治疗：德国霍奇金研究组的一项 2 期随机试验的最终分析。
Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10.
3
Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.因先天性肝内胆管缺如综合征导致肝功能障碍的霍奇金淋巴瘤患者接受 Brentuximab vedotin 治疗后获得部分缓解，且无严重不良事件。
J Clin Exp Hematop. 2022 Sep 28;62(3):154-157. doi: 10.3960/jslrt.21035. Epub 2022 Jul 12.
4
Intrahepatic cholestasis related to vanishing bile duct syndrome in Hodgkin's disease.霍奇金病中与胆管消失综合征相关的肝内胆汁淤积
J Pediatr Gastroenterol Nutr. 1997 Apr;24(4):430-3. doi: 10.1097/00005176-199704000-00013.
5
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
6
Vanishing bile duct syndrome in a Hodgkin's lymphoma patient with fatal outcome despite lymphoma remission.霍奇金淋巴瘤患者发生消失性胆管综合征，尽管淋巴瘤缓解但仍导致死亡。
Saudi J Gastroenterol. 2013 Nov-Dec;19(6):286-9. doi: 10.4103/1319-3767.121037.
7
Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.霍奇金淋巴瘤成功治疗后副肿瘤性胆管消失综合征完全缓解：一例报告并文献复习
BMC Res Notes. 2014 Aug 14;7:529. doi: 10.1186/1756-0500-7-529.
8
Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.霍奇金淋巴瘤中的胆管消失综合征：一例报告及文献复习
World J Gastroenterol. 2017 Jan 14;23(2):366-372. doi: 10.3748/wjg.v23.i2.366.
9
Tumour-directed radiotherapy as a successful bridge to curative chemotherapy in early stage Hodgkin's lymphoma-associated vanishing bile duct syndrome.肿瘤定向放疗作为早期霍奇金淋巴瘤相关消失性胆管综合征治愈性化疗的有效桥梁。
BMJ Case Rep. 2024 Sep 24;17(9):e261879. doi: 10.1136/bcr-2024-261879.
10
Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) in Hodgkin's disease: report of a case.霍奇金病伴胆管减少（消失性胆管综合征）的胆汁淤积性肝病：病例报告
Tumori. 2004 Sep-Oct;90(5):517-20. doi: 10.1177/030089160409000516.
引用本文的文献
1
Case Report: Vanishing bile duct syndrome in Hodgkin's lymphoma: a case highlighting jaundice and lymphadenopathy as early clues.病例报告：霍奇金淋巴瘤中的胆管消失综合征：一例以黄疸和淋巴结病为早期线索的病例
Front Immunol. 2025 May 21;16:1561110. doi: 10.3389/fimmu.2025.1561110. eCollection 2025.
2
Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen.成功用博来霉素、依托泊苷、多柔比星、长春新碱和达卡巴嗪方案治疗霍奇金淋巴瘤相关的进行性肝内胆汁淤积症。
BMJ Case Rep. 2023 Nov 21;16(11):e257211. doi: 10.1136/bcr-2023-257211.
3
Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.因先天性肝内胆管缺如综合征导致肝功能障碍的霍奇金淋巴瘤患者接受 Brentuximab vedotin 治疗后获得部分缓解，且无严重不良事件。
J Clin Exp Hematop. 2022 Sep 28;62(3):154-157. doi: 10.3960/jslrt.21035. Epub 2022 Jul 12.
4
Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.膈上经典型霍奇金淋巴瘤伴副肿瘤性肝内胆汁淤积经 Brentuximab Vedotin 成功治疗：病例报告及文献复习。
In Vivo. 2021 Jul-Aug;35(4):1951-1957. doi: 10.21873/invivo.12462.
本文引用的文献
1
Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.霍奇金淋巴瘤成功治疗后副肿瘤性胆管消失综合征完全缓解：一例报告并文献复习
BMC Res Notes. 2014 Aug 14;7:529. doi: 10.1186/1756-0500-7-529.
2
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
3
Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review.霍奇金淋巴瘤相关的胆管消失综合征和特发性胆汁淤积：所有已发表病例的统计分析及文献综述
Acta Oncol. 2008;47(5):962-70. doi: 10.1080/02841860701644078.
4
[Ductal regeneration in vanishing bile duct syndrome in Hodgkin's lymphoma].[霍奇金淋巴瘤中消失性胆管综合征的胆管再生]
Gastroenterol Hepatol. 2005 May;28(5):275-8. doi: 10.1157/13074061.
5
Cholestasis secondary to Hodgkin's disease: report of 2 cases of vanishing bile duct syndrome.霍奇金病继发胆汁淤积：2例消失胆管综合征报告
Haematologica. 1998 Nov;83(11):1038-40.
6
Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease.霍奇金病成功治疗后副肿瘤性胆管稀少的消退
Hepatology. 1997 Jul;26(1):5-8. doi: 10.1002/hep.510260101.
7
Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.多柔比星在小细胞肺癌患者中的药代动力学和药效学
Clin Pharmacol Ther. 1993 May;53(5):555-61. doi: 10.1038/clpt.1993.69.
8
The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.
Cancer Chemother Pharmacol. 1982;8(2):215-9. doi: 10.1007/BF00255487.
9
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.阿霉素化疗——间歇性单次高剂量方案的疗效、安全性及药理学基础
Cancer. 1974 Jan;33(1):19-27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m.
10
The effects of impaired liver function on the elimination of antineoplastic agents.肝功能受损对抗肿瘤药物消除的影响。
Ann Pharmacother. 1992 Mar;26(3):363-71. doi: 10.1177/106002809202600311.
Zotero 插件